

**CSE: VP**

**FSE: 1JV1**

**NEWS RELEASE**

 **NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH UNITED STATES NEWSWIRE SERVICES /**

**Vodis Announces Postponement of AGM**

December 21, 2018, Vancouver, British Columbia – **Vodis Pharmaceuticals Inc.** (CSE: VP, FSE: 1JV1) (“**Vodis**” or the “**Company**”) announces the annual general meeting scheduled for Tuesday, January 22, 2019, has been postponed. The new date for the meeting will be communicated in due course.

**About Vodis Pharmaceuticals Inc.**

Vodis is one of North America’s foremost brand names in the medical and recreational marijuana business with operations in both the United States and Canada. Its master grow teams have consistently won or placed at each Canadian competition they have entered with their “VIP” brand. The Company, with facilities in British Columbia and Washington State, is also actively looking into expansion opportunities in other countries and throughout the United States.

While Vodis and its subsidiaries cannot have any interest whatsoever in any proceeds as a result of production, processing or retail activities in the United States, it can license its brand, production and consulting services to approved Washington State licence holders to ensure that all products produced under the Vodis Pharmaceuticals program and/or associated under the VIP brand meet or exceed Vodis-brand quality standards.

For further information please contact:

Ivan Miliovski, Chief Executive Officer
Vodis Pharmaceuticals Inc.
1-866-210-1420 Ext103

-or-

Soy Garipoglu
Investor Relations
Vodis Pharmaceuticals Inc.
8788 River Road
Delta, BC V4G 1B4
Contact: 778-990-8985
Email: investorrelations@vodis.ca
Web: www.vodis.ca

**The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.**